HIV Injection Market to Witness Tremendous Growth, USD 5.5 Billion by 2033, Claims AMR

Allied Market Research published a report, titled, “HIV Injection Market by Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacies, and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the global HIV injection industry generated $1.0 billion in 2023, and is anticipated to generate $5.5 billion by 2033, witnessing a CAGR of 17.9% from 2024 to 2033.

HIV Injection Market Drivers

The growth of the HIV injection market is fueled by an increase in the number of individuals affected by HIV, greater awareness surrounding early diagnosis and treatment, and a rise in research and development initiatives. For example, as reported by the World Health Organization (WHO) in July 2023, HIV continues to be a significant global public health concern, with advanced HIV disease remaining a persistent issue in HIV response efforts. According to the same source, approximately 39.0 million people were living with HIV by the end of 2022, and around 1.3 million people acquired HIV in that same year.

Request Sample of the Report on HIV Injection Market Forecast 2033 https://www.alliedmarketresearch.com/request-sample/A312373

Report Coverage and Details: 

Report Coverage	Details
Forecast Period	2024–2033
Base Year	2023
Market Size In 2022	$1.0 Billion
Market Size In 2032	$5.5 Billion
CAGR	17.9%
No. Of Pages In Report	197
Segments Covered	Distribution Channel And Region
Drivers	Rise In Number Of People Receiving HIV Therapy
Opportunities	Growing Awareness And Initiatives Taken By Government For HIV
	Rise In Number Of Product Approvals
	High Growth Potential In Emerging Markets
	Rise In Number Of Pipeline Products
Restraint	Stringent Regulatory Product Approvals

Recession Impact 

During an economic downturn, both individuals and governments may tighten their budgets, resulting in decreased healthcare spending. This could limit patients’ access to and affordability of HIV injections, potentially reducing demand for such treatments. However, the increasing prevalence of HIV infections sustains demand for therapeutic drugs, even during a recession. Consequently, there may be a moderately positive impact on the demand for HIV injections, driven by the rising need for treatment amidst economic challenges.

Recent Developments in the HIV Injection Industry

• In October 2023, ViiV Healthcare, the global specialist HIV company with majority owned by GSK announced that the National Medical Products Administration (NMPA) of China approved Vocabria (cabotegravir injection) used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
• In September 2023, ViiV Healthcare, the global specialist HIV company with majority owned by GSK, announced that the European Commission has authorised Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention.
• In February 2023, Gilead Sciences, Inc. announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing.Results fromthe Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV.
• In January 2022, ImmunityBio, Inc., a clinical-stage immunotherapy company announced promising study results that demonstrate the activation of CD4+ and CD8+ T cells and natural killer (NK) cells in people living with HIV by ImmunityBio’s IL-15 superagonist Anktiva (N-803). Anktiva stimulates latent HIV replication (the “kick”) in CD4 memory cells allowing the previously hidden infected cells to be revealed and eliminated (the “kill”) by CD8 and NK cells.

Inquiry Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/A312373

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.

Key Findings of the Study

• By distribution channel, the others segment dominated the HIV injection market size in 2023.
• Region-wise, North America held the largest HIV injection market size in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
• India is expected to grow at a significant CAGR of 22.7% during the forecast period.
• In Europe, Germany held the largest share in the HIV injection market in 2023.
• Brazil is anticipated to grow at a significant CAGR of 21.5% during the forecast period.

Leading Market Players

• GlaxoSmithKline plc
• Johnson and Johnson
• Gilead Sciences, Inc.
• ImmunityBio, Inc.
• F. Hoffmann-La Roche Ltd.
• Theratechnologies Inc.
• Viriom, Inc.
• AbbVie Inc.
• Brii Biosciences
• Shionogi and Co., Ltd.

Reasons to Buy this HIV Injection Market Report:

> Mergers and acquisitions should be well-planned by identifying the best manufacturer.

> Sort new clients or possible partners into the demographic you’re looking for.

> Suitable for providing dependable and high-quality data and analysis to assist your internal and external presentations.

> Develop tactical initiatives by gaining a better grasp of the areas in which huge corporations can intervene.

> To increase and grow business potential and reach, develop and plan licencing and licencing strategies by finding possible partners with the most appealing projects.

> Recognize newcomers with potentially strong product portfolios and devise effective counter-strategies to acquire a competitive edge.

> To develop effective R&D strategies, gather information, analysis, and strategic insight from competitors.

Related Reports :

Histology and Cytology Market https://www.alliedmarketresearch.com/histology-and-cytology-market-A15397 Ocular Drug Delivery Market https://www.alliedmarketresearch.com/ocular-drug-delivery-market